WA
Avstera develops novel therapeutics by leveraging immunological cell insights to address diseases with significant unmet needs. The company's lead program is an IND-cleared, highly selective oral HDAC6i immunomodulator targeting difficult-to-treat cancers. Their preclinical pipeline also features next-generation oral HDAC6i candidates for cardiometabolic and cardiovascular indications.
Updated 2 months ago
Funding
$9.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Avstera develops novel therapeutics by leveraging immunological cell insights to address diseases with significant unmet needs. The company's lead program is an IND-cleared, highly selective oral HDAC6i immunomodulator targeting difficult-to-treat cancers. Their preclinical pipeline also features next-generation oral HDAC6i candidates for cardiometabolic and cardiovascular indications.